Osivax announced today that it has received over EUR 30M in public funding from different sources to support the development of universal vaccines against coronavirus and influenza. The Company’s proprietary oligoDOM®...

By NewsDesk  @infectiousdiseasenews Health officials report a national COVID-19 case count of 599,705 confirmed cases, including 8,359 deaths. The City of Moscow and the Moscow region account for more...

Biotechnology company, Novavax, Inc. today announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein...

By NewsDesk  @infectiousdiseasenews  Over the past week, New Zealand health officials have reported one COVID-19 case over the past week. The last case since May 18 was reported on May 22 was linked...

Clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, Moderna, Inc.,  announced Monday positive interim clinical data of mRNA-1273, its vaccine candidate against...

Researchers worldwide are racing at breakneck speed to develop potential vaccines and drugs to fight the novel coronavirus, SARS-Cov-2. Now, the United States Patent and Trademark Office (USPTO) has granted...

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that it has initiated a program to develop a...